Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 4/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | MAPT | P10636 | 4/20 | 0.57 |
| ▸ | THRB | P10828 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29831415 | 0.81 | MAPT (0.57) | TP53SMN1; SMN2MAPTTHRBGAA | |
| SCHEMBL17552174 | 0.81 | MAPT (0.57) | TP53SMN1; SMN2MAPTTHRBGAA | |
| SCHEMBL28439562 | 0.81 | MAPT (0.65) | TP53MAPTTHRBGAAALDH1A1 | |
| SCHEMBL21313822 | 0.80 | MAPT (0.59) | TP53SMN1; SMN2MAPTTHRBGAA | |
| SCHEMBL4711326 | 0.79 | MAPT (0.63) | TP53MAPTTHRBGAAALDH1A1 | |
| SCHEMBL26798510 | 0.76 | ALDH1A1 (0.54) | TP53SMN1; SMN2MAPTTHRBGAA | |
| SCHEMBL29911200 | 0.76 | MAPT (0.58) | TP53SMN1; SMN2MAPTTHRBGAA | |
| SCHEMBL19422864 | 0.76 | MAPT (0.58) | TP53SMN1; SMN2MAPTTHRBGAA | |
| SCHEMBL21019963 | 0.76 | MAPT (0.45) | TP53SMN1; SMN2MAPTTHRBGAA | |
| SCHEMBL17552177 | 0.75 | MAPT (0.64) | TP53MAPTTHRBGAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250248990-A1 | QUINOLINES THAT MODULATE SERCA AND THEIR USE FOR TREATING DISEASE | NEURODON CORPORATION | 2025-08-07 | — | — | US | disclosed |
| US-12144806-B2 | Quinolines that modulate SERCA and their use for treating disease | NEURODON CORPORATION (US) | 2024-11-19 | — | — | US | disclosed |
| US-20240277694-A1 | QUINOLINES THAT MODULATE SERCA AND THEIR USE FOR TREATING DISEASE | NEURODON CORPORATION | 2024-08-22 | — | — | US | disclosed |
| US-11992487-B2 | Quinolines that modulate SERCA and their use for treating disease | NEURODON CORPORATION (US) | 2024-05-28 | — | — | US | disclosed |
| EP-4037685-B9 | QUINOLINE THAT MODULATE SERCA AND ITS USE FOR TREATING DISEASE | NEURODON CORP (US) | 2024-03-06 | — | — | EP | disclosed |
| US-20240016793-A1 | QUINOLINES THAT MODULATE SERCA AND THEIR USE FOR TREATING DISEASE | NEURODON CORPORATION | 2024-01-18 | — | — | US | disclosed |
| US-20240016793-A1 | QUINOLINES THAT MODULATE SERCA AND THEIR USE FOR TREATING DISEASE | NEURODON CORPORATION | 2024-01-18 | — | — | US | disclosed |
| US-11827626-B2 | Quinolines that modulate SERCA and their use for treating disease | NEURODON CORPORATION (US) | 2023-11-28 | — | — | US | disclosed |
| US-11827626-B2 | Quinolines that modulate SERCA and their use for treating disease | NEURODON CORPORATION (US) | 2023-11-28 | — | — | US | disclosed |
| EP-4037685-B1 | QUINOLINE THAT MODULATE SERCA AND ITS USE FOR TREATING DISEASE | NEURODON CORP (US) | 2023-09-20 | — | — | EP | disclosed |
| US-11730729-B2 | Quinolines that modulate SERCA and their use for treating disease | NEURODON CORPORATION (US) | 2023-08-22 | — | — | US | disclosed |
| US-11730729-B2 | Quinolines that modulate SERCA and their use for treating disease | NEURODON CORPORATION (US) | 2023-08-22 | — | — | US | disclosed |
| US-20220016108-A1 | QUINOLINES THAT MODULATE SERCA AND THEIR USE FOR TREATING DISEASE | NEURODON CORPORATION | 2022-01-20 | — | — | US | disclosed |
| US-20200347038-A1 | QUINOLINES THAT MODULATE SERCA AND THEIR USE FOR TREATING DISEASE | NEURODON CORPORATION | 2020-11-05 | — | — | US | disclosed |
| US-10772881-B2 | Quinolines that modulate SERCA and their use for treating disease | NEURODON CORPORATION | 2020-09-15 | — | — | US | disclosed |
| US-20190151303-A1 | QUINOLINES THAT MODULATE SERCA AND THEIR USE FOR TREATING DISEASE | NEURODON CORPORATION | 2019-05-23 | — | — | US | disclosed |
| US-20170281611-A1 | QUINOLINES AND THEIR USE FOR TREATING ENDOPLASMIC RETICULUM STRESS-CAUSED DISEASES | EIGER BIOPHARMACEUTICALS, INC. (US) | 2017-10-05 | — | — | US | disclosed |
| WO-2016032569-A1 | QUINOLINES AND THEIR USE FOR TREATING ENDOPLASMIC RETICULUM STRESS-CAUSED DISEASES | CELLADON CORPORATION (US) | 2016-03-03 | — | — | WO | disclosed |
| WO-2016032569-A1 | QUINOLINES AND THEIR USE FOR TREATING ENDOPLASMIC RETICULUM STRESS-CAUSED DISEASES | CELLADON CORPORATION (US) | 2016-03-03 | — | — | WO | disclosed |
| US-9029407-B2 | Aminothiazole modulators of beta-3-adrenoreceptor | AUSPEX PHARMACEUTICALS, INC. (US) | 2015-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170281611-A1 | QUINOLINES AND THEIR USE FOR TREATING ENDOPLASMIC RETICULUM STRESS-CAUSED DISEASES | ATP2A1, ATP2A3, ATP2A2 | TP53 3254/4885SMN1; SMN2 698/4885MAPT 1538/4885 |
| US-11992487-B2 | Quinolines that modulate SERCA and their use for treating disease | ATP2A1, ATP2A3, ATP2A2 | TP53 3732/4885SMN1; SMN2 326/4885MAPT 1228/4885 |
| US-12144806-B2 | Quinolines that modulate SERCA and their use for treating disease | ATP2A1, ATP2A3, ATP2A2 | TP53 3732/4885SMN1; SMN2 326/4885MAPT 1228/4885 |
| US-20250248990-A1 | QUINOLINES THAT MODULATE SERCA AND THEIR USE FOR TREATING DISEASE | ATP2A1, ATP2A3, ATP2A2 | TP53 3732/4885SMN1; SMN2 326/4885MAPT 1228/4885 |
| US-10772881-B2 | Quinolines that modulate SERCA and their use for treating disease | ATP2A1, ATP2A3, ATP2A2 | TP53 3639/4885SMN1; SMN2 270/4885MAPT 1307/4885 |
| US-11730729-B2 | Quinolines that modulate SERCA and their use for treating disease | ATP2A1, ATP2A3, ATP2A2 | TP53 3732/4885SMN1; SMN2 326/4885MAPT 1228/4885 |
| US-11827626-B2 | Quinolines that modulate SERCA and their use for treating disease | ATP2A1, ATP2A3, ATP2A2 | TP53 3732/4885SMN1; SMN2 326/4885MAPT 1228/4885 |
| US-20240277694-A1 | QUINOLINES THAT MODULATE SERCA AND THEIR USE FOR TREATING DISEASE | ATP2A1, ATP2A3, ATP2A2 | TP53 3732/4885SMN1; SMN2 326/4885MAPT 1228/4885 |
| US-20190151303-A1 | QUINOLINES THAT MODULATE SERCA AND THEIR USE FOR TREATING DISEASE | ATP2A1, ATP2A3, ATP2A2 | TP53 3639/4885SMN1; SMN2 270/4885MAPT 1307/4885 |
| US-20220016108-A1 | QUINOLINES THAT MODULATE SERCA AND THEIR USE FOR TREATING DISEASE | ATP2A1, ATP2A3, ATP2A2 | TP53 3732/4885SMN1; SMN2 326/4885MAPT 1228/4885 |
| US-20200347038-A1 | QUINOLINES THAT MODULATE SERCA AND THEIR USE FOR TREATING DISEASE | ATP2A1, ATP2A3, ATP2A2 | TP53 3732/4885SMN1; SMN2 326/4885MAPT 1228/4885 |
| US-20240016793-A1 | QUINOLINES THAT MODULATE SERCA AND THEIR USE FOR TREATING DISEASE | ATP2A1, ATP2A3, ATP2A2 | TP53 3732/4885SMN1; SMN2 326/4885MAPT 1228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.